CDK4 and neoplasm: Only those molecules that (i) demonstrated selective cytotoxicity (SI > 2 in at least one tumor cell line) and (ii) showed strong molecular docking affinity toward VEGFR2 and/or CDK4 were advanced to redox-related assays.